Tumour targeting with rationally modified cell-penetrating peptides

International Journal of Peptide Research and Therapeutics

Volumn 18, Issue 4, 2012, Pages 361-371

  Mae, Maarja ^a,b   Rautsi, Outi ^a,c   Enback, Juulia ^c   Hallbrink, Mattias ^b   Aizman, Katri Rosenthal ^d,e   Lindgren, Maria ^a   Laakkonen, Pirjo ^c   Langel, Ulo ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Dilafortte AB   (Sweden)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cell penetrating peptide; Imaging; Matrix metalloproteinase; Targeting

Indexed keywords

CELL PENETRATING PEPTIDE; ENZYME INHIBITOR; FLUORESCINYL CARBOXYLIC ACID; GELATINASE A; GELATINASE A INHIBITOR; ISOLEUCYLALANYLTRYPTOPHANYLVALYLLYSYLALANYLPHENYLALANYLISOLEUCYLARGINYLLYSYLGLYCYLPROLYLLEUCYLGLYCYLAMIDE; ISOLEUCYLALANYLTRYPTOPHANYLVALYLLYSYLALANYLPHENYLALANYLISOLEUCYLARGINYLLYSYLGLYCYLPROLYLLEUCYLGLYCYLISOLEUCYLALANYLGLYCYLGLUTAMYLASPARTYLGLYCYLASPARTYLGLUTAMYLGLYCYLPHENYLALANYLAMIDE; METHOTREXATE; RECOMBINANT ENZYME; RECOMBINANT GELATINASE A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DOSAGE FORM COMPARISON; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMAGING; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN MODIFICATION; TUMOR XENOGRAFT;

MUS;

EID: 84871921595     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-012-9312-1     Document Type: Article

References (25)

1. Bauvois B (2004) Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23:317-329 (Pubitemid 38174985)
2. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392 (Pubitemid 34270240)
3. Goun EA, Shinde R, Dehnert KW, Adams-Bond A, Wender PA, Contag CH, Franc BL (2006) Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. Bioconjug Chem 17:787-796 (Pubitemid 43794390)
4. Hansen M, Kilk K, Langel Ü (2008) Predicting cell-penetrating peptides. Adv Drug Deliv Rev 60:572-579 (Pubitemid 351215574)
5. Holm T, Johansson H, Lundberg P, Pooga M, Lindgren M, Langel Ü (2006) Studying the uptake of cell-penetrating peptides. Nat Protoc 1:1001-1005
6. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY (2004) Tumor imaging by means of proteolytic activation of cellpenetrating peptides. Proc Natl Acad Sci USA 101:17867-17872 (Pubitemid 40051978)
7. Karlström A, Undén A (1996) Design of protecting groups for the betacarboxylic group of aspartic acid that minimize base-catalyzed aspartimide formation. Int J Pept Protein Res 48:305-311 (Pubitemid 26366816)
8. Kastrup B, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbaek K (2008) Genetic and epigenetic alterations of the reduced folatecarrier in untreated diffuse large B-cell lymphoma. Eur J Haematol 80:61-66 (Pubitemid 350265231)
9. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES (2004) The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 50:87-100 (Pubitemid 38638736)
10. Kurrikoff K, Suhhorutshenko J, Langel Ü (2012) Cell-penetrating peptides in cancer targeting. In: Kratz F, Senter P, Steinhagen H (eds) Drug delivery in oncology. From basic research to cancer therapy, vol 3. Wiley-VCH Verlag GmbH & Co.KGaA, Weinheim, pp 1189-1217
11. Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, Krieg T, Mauch C (1999) Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 274:21056-21062
12. Laakkonen P, Vuorinen K (2010) Homing peptides as targeted delivery vehicles. Integr Biol (Camb) 2:326-337
13. Lauer JL, Fields CG, Fields GB (1994) Sequence dependence of aspartimide formation during Fmoc solid phase synthesis. Lett Pept Sci 1:197-205
14. Lindberg S, Copolovici DM, Langel Ü (2011) Therapeutic delivery opportunities, obstacles and applications for cell-penetrating peptides. Ther Deliv 2:71-82
15. Lindgren M, Rosenthal-Aizman K, Saar K, Eiriksdottir E, Jiang Y, Sassian M,Ö stlund P, Hällbrink M, LangelÜ (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71:416-425 (Pubitemid 43077076)
16. Mäger I, Eiriksdottir E, Langel K, El Andaloussi S, Langel Ü (2010) Assessing the uptake kinetics and internalization mechanisms of cell-penetrating peptides using a quenched fluorescence assay. Biochim Biophys Acta 1798:338-343
17. Myrberg H, Zhang L, Mäe M, Langel Ü (2008) Design of a tumorhoming cell-penetrating peptide. Bioconjug Chem 19:70-75
18. Papparella S, Restucci B, Paciello O, Maiolino P (2002) Expression of matrix metalloprotease-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. J Comp Pathol 126:271-276
19. Pipkorn R, Waldeck W, Spring H, Jenne JW, Braun K (2006) Delivery of substances and their target-specific topical activation. Biochim Biophys Acta 1758:606-610 (Pubitemid 43927588)
20. Rutges JP, Kummer JA, Oner FC, Verbout AJ, Castelein RJ, Roestenburg HJ, Dhert WJ, Creemers LB (2008) Increased MMP-2 activity during intervertebral disc degeneration is correlated to MMP-14 levels. J Pathol 214:523-530 (Pubitemid 351340573)
21. Schönherr E, Schaefer L, O'Connell BC, Kresse H (2001) Matrix metalloproteinase expression by endothelial cells in collagen lattices changes during co-culture with fibroblasts and upon induction of decorin expression. J Cell Physiol 187:37-47 (Pubitemid 32195243)
22. Seiki M, Mori H, Kajita M, Uekita T, Itoh Y (2003) Membrane-type 1 matrix metalloproteinase and cell migration. Biochem Soc Symp 70:253-262 (Pubitemid 38497231)
23. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M (1995) Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MTMMP) and with lymph node metastasis. Int J Cancer 64:355-359
24. Vivès E, Schmidt J, Pèlegrin A (2008) Cell-penetrating and celltargeting peptides in drug delivery. Biochim Biophys Acta 1786:126-138
25. Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG (2011) Knockdown of human antigen R reduces the growth and invasion of breast cancer cells in vitro and affects expression of cyclin D1 and MMP-9. Oncol Rep 26:237-245